Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2004

View Archived Issues

New formulations comprising epinastine

Antibacterial ketolides claimed by Taisho

New compounds for neurological disorders described in a patent

Ono claims elastase inhibitors for COPD, pulmonary emphysema, rheumatoid arthritis, etc.

Researchers at Aponetics describe apoptosis-inducing agents

New HDAC inhibitors described by Roche

New antioxidants in early development at Japan Science and Technology

Camptothecin combinations for the treatment of tumors

MT-201 cleared to enter phase II U.S. trial in metastatic breast cancer

BioMarin and Suntory form strategic partnership for Phenoptin

Enrollment completed in phase II lipodystrophy study of EG-005

Pipeline progression at Antisoma

Gedeon Richter and Forest collaborate on atypical antipsychotic RGH-188

deCODE genetics and Roche establish PDE4 inhibitor collaboration

Confirmatory phase III study for Frova opens enrollment

SRP-299 discontinued for moderate to severe pediatric atopic dermatitis

Sirna-027 enters phase I study for wet AMD

Positive preliminary results from phase I/II study of PA-457

Specific Akt inhibitor shows antiproliferative and antiapoptotic effects

Novel orally available PDGFR inhibitors from Millennium

VEGFR vaccine blocks initiation and progression of atherosclerosis

Cytochroma cleared to begin Canadian phase Ia study of CTA-018 for psoriasis

Pivotal generalized anxiety disorder study under way for ocinaplon

Phase II NSCLC trial of KOS-862 discontinued

Tysabri approved for multiple sclerosis

Intravenous use of Remodulin approved for pulmonary arterial hypertension

Nicaraven cardioprotective in sepsis model

Update on the effects and safety of veglin in refractory cancer

Statins may decrease mortality in pneumonia patients

ChimeriVax-JE reported safe and immunogenic in healthy volunteers

Antitumor efficacy and safety of a panitumumab-based regimen in colorectal cancer

Isatoribine reduces HCV viral load in patients with chronic hepatitis C

Therapeutic benefits of the Enteryx(R) procedure in GERD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...